Key Drivers
- Strong liquidity
- Severe losses
- Minimal revenue
AIAI Summary
Celldex has shifted from an early‑stage R&D story to a late‑stage, binary investment where Phase 3 execution and readouts (not narrative) will drive valuation, making barzolvolimab's trial outcomes the single most important catalyst. Investors should size positions around upcoming EMBARQ-CSU1/2 readouts and closely monitor cash burn/financing timing—positive data could re-rate materially, while trial failure or delays will likely force dilution and steep downside.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •Severe losses
- •Minimal revenue
Cellectis combines strong liquidity and minimal leverage with severe operating losses, negligible revenue and large cash burn, leaving a high-capital-risk profile despite a healthy balance sheet. #high-burn #strong-balance
Price Behavior
Key Price Behavior Insights:
- •Strong uptrend
- •Gap breakout
- •Mean-reversion risk
Over last month the stock rallied ~34% from $23.02 to $30.90 on a concentrated gap breakout (~$24.84→$30.82), forming higher highs/lows but facing resistance at $31.23 and vulnerable to a pullback if it fails to hold the high-$29s.
Concentrated gap from $24.84 to $30.82 driving a rapid ~34% move and higher realized volatility
Sentiment & News
Key News Insights:
- •Phase 3 enrollment
- •Sustained efficacy
- •Rapid retreatment
Celldex completed global Phase 3 enrollment for barzolvolimab, reported favorable Phase 2 AAAAI readouts showing sustained and retreatment efficacy across CSU/ColdU/SD, and issued FY2025 results and corporate updates.
Completed enrollment plus supportive Phase 2 data materially de-risks the barzolvolimab program and could provide near-term upside for Celldex
Similar Companies in Healthcare
Other companies in the same sector with AI ratings